CHMP Issues Positive Opinion On Ipsen's Cabometyx For Advanced PNET And EpNET Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 20 2025
0mins
Source: NASDAQ.COM
Positive Opinion for Cabometyx: Ipsen announced that the European Medicines Agency's CHMP has given a positive opinion for Cabometyx (cabozantinib) to treat adult patients with unresectable or metastatic neuroendocrine tumors who have progressed after prior therapy.
Pending Final Approval: A final decision on the approval of Cabometyx in the European Union is anticipated in the coming months, based on data from the CABINET Phase III trial.
Analyst Views on EXEL
Wall Street analysts forecast EXEL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 44.09 USD with a low forecast of 30.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
7 Buy
8 Hold
1 Sell
Moderate Buy
Current: 44.500
Low
30.00
Averages
44.09
High
52.00
Current: 44.500
Low
30.00
Averages
44.09
High
52.00
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
